GE HealthCare Technologies
✦ Quant Fair Value how this is computed
- Implied fair-value range of 69.22-106.96, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -8.5% below the average-multiple fair value of 88.09.
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| GE HealthCare Technologies (GEHC) | 36.46B | 17.05 | 3.14 | 0.17% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 9.1% below Morningstar's fair value estimate.
Analyst note
Organic year-on-year revenue growth for the quarter was 6.2% and adjusted EBIT margin was 16.6%, or 180 basis points better than the prior year period. Management raised full-year guidance for organic revenue growth to 4% from 3%-4%. Shares closed 7% higher than the previous day's close.
Why it matters: The result beats expectations, while full-year guidance remains in line with our forecast. Both metrics reaffirm our view that GE Healthcare is making remarkable progress on improving margin despite substantial pressure from inflation and tariffs. Although full-year guidance implies slower fourth-quarter organic growth of 3%-4%, we still expect over 100 basis points of year-on-year adjusted EBIT margin expansion for the quarter and 20-40 basis points of improvement for the full year. Advanced imaging solutions, pharmaceutical diagnostics, and patient care solutions posted 4.5%, 13.8%, and 8.8% organic year-on-year revenue growth, respectively. All segments reported stronger margins, including PCS, which recovered from a negative 3.8% EBIT margin last quarter to 8.6% this quarter.
The bottom line: We maintain our fair value estimate of $88 per share for wide-moat GEHC. Even after today’s rally, we view shares as modestly undervalued and trading near the border of 3-star and 4-star territory. We believe GEHC’s new product launches and operational improvements will help it overcome margin pressure from inflation, tariffs, and higher memory chip prices. Although tariffs remain a major swing factor, supply chain actions are partially mitigating them. Organic orders growth was 4%, in line with our midterm growth forecast. Although the quarterly book/bill ratio fell to 1.03, we attribute this mostly to better order fulfillment. On a trailing-12-month basis, we estimate the ratio was 1.08, slightly better than 1.07 in 2025.
Fair value
We are keeping our fair value estimate at $88 per share.
During our five-year explicit forecast period, we project revenue to grow in the low to mid-single digits. To account for the uncertainty posed by recent trade tensions between the US and the rest of the world, this is slightly below our assumptions for economic and healthcare spending growth in the territories where GEHC sells.
We project EBIT margin to rise from 14.2% in 2025 to 15.7% by 2030. Gross profit margin has been improving due to product mix shifts, and management has made progress in lowering operating expenses and optimizing its cost structure after its spinout. However, starting in 2026, GEHC has faced inflationary pressure on freight and input costs, so we have toned down our expectations of profit margin improvement.
For our 15-year stage two forecast period, we project normalized earnings growth of low single digits, in line with our projections for economic growth and healthcare spending growth in the territories that GEHC sells into.
We subtract the company's unfunded pension liabilities, which were $4.4 billion at the end of 2025, from our enterprise value.
We assume a weighted average cost of capital of 6.7%.
Economic moat
We award a Wide Morningstar Economic Moat Rating to GE HealthCare based primarily on intangible assets and switching costs in its imaging and ultrasound segments, which constitute over 70% of total revenue. Intangible assets include GEHC’s comprehensive product catalogue of cutting-edge products and extensive servicing networks. Switching costs primarily consist of the integration of its hardware and software ecosystems into hospital workflows and servicing contracts for long-lived capital equipment. Across its segments, its competitive advantages are tied to its scale and integration into healthcare systems, and we think it would be very hard to displace GEHC in these businesses within 20 years.
The advanced imaging solutions segment (about 60% of revenue) sells medical imaging equipment based on various technologies, including X-ray, computed tomography, magnetic resonance imaging, molecular imaging, and ultrasound. It also includes procedural guidance systems. These machines are used in a large number of medical procedures across therapeutic areas. The expensive technologies like CT, MRI, MI, and procedural guidance machines tend to be purchased by hospitals, provider networks, imaging centers, and surgical centers with sufficient patient flow to support owning such high-cost equipment. GEHC also sells servicing contracts and digital solutions. It is a top-three global player along with Siemens Healthineers and Philips, and we see a strong moat in this business.
Medical imaging and procedural guidance equipment requires precision engineering and extensive research and development to stay at the cutting edge. Only a handful of players are large enough to offer a comprehensive product catalogue that is competitive across all major imaging modalities. Each of the three largest players spent $1 billion-$2 billion per year on R&D. We think the market is an oligopoly structure where the largest players compete on product features and innovations rather than outright price.
Having the necessary scale to be a one-stop shop is especially important for selling to larger purchasers such as hospitals and large healthcare networks, which we think is a sticky customer base. By offering a full suite of equipment and software, GEHC can integrate its products into hospital workflows and bundle products and services during negotiations. It is common for hospitals and provider networks to procure most of their imaging equipment from a single supplier and enter a servicing contract for maintenance and repair. Furthermore, they are reluctant to change their equipment and software vendors due to potential disruption of workflows.
GEHC has built out extensive global servicing networks, which provide an important source of recurring, high-margin revenue. We estimate its contribution could be in the context of 40% of segment revenue. Imaging equipment often has long lifecycles, and big-ticket equipment can be used for 10-15 years before being sold on the secondary market. It is important for imaging facilities that their equipment is always functional, as rescheduling procedures can hurt revenue and delay timely treatment. GEHC’s extensive network of field engineers enables it to offer 24-hour troubleshooting and repair services, adopting the razor-and-blade business model seen across the medical equipment and life sciences industry. Although servicing contracts are not captive and do not typically span the lifetime of the equipment, across the industry, we estimate approximately 70% of customers will contract with the same servicer as the equipment maker. For many purchasers with high patient flow, maximizing up time is perhaps even more important than upfront equipment costs. Combined with the oligopoly market structure and reluctance of larger purchasers to change vendors, we see long-lasting economic moats for advanced imaging solutions.
The patient care solutions segment (15% of revenue) consists of a wide variety of medical devices used in acute care, including surgery and patient monitoring settings. Although there are trace switching costs and intangibles scattered throughout the business, we do not think this segment warrants a moat, given lower profitability and the overall competitiveness of these markets.
The pharmaceutical diagnostics segment (14% of revenue) consists of various contrast media used in ultrasound, MRI, X-rays, angiography, and CT, and radiotracers used in MI (including positron emission tomography and single photon emission CT). We think this segment has strong moats backed by its reputation for stable supply and high-quality manufacturing processes. Contrast media constitute about 80% of this segment, and GEHC is a top player along with Bracco Diagnostics and Bayer. Although contrast media do not have a lot of product innovation and there is some degree of substitutability within the same class of contrast agent, it is a strictly regulated industry, so vendors must have stringent quality controls and pharmacovigilance. Furthermore, it is a mission-critical consumable for certain types of imaging and interventional procedures (including angiography), and any shortage or delay in supply can be detrimental to workflows.
Radiotracers constitute the remaining 20% of GEHC’s patient diagnostics segment, and it is currently a fragmented market. These diagnostic pharmaceuticals are radioactive and require additional care for logistics. Because of their short half-lives, doses are individually made to order for a scheduled PET exam and delivered via express to the administering provider. We believe that building out the infrastructure and track record for this segment is a significant barrier to entry. Growth drivers in this product category include Flyrcado (used in myocardial perfusion imaging to detect ischemia and infarction), Vizamyl (amyloid detection for Alzheimer's disease), and Cerianna (estrogen receptor imaging in breast cancer).
Bull case
Now that it has been spun off, GEHC is able to focus on R&D and operational efficiency without competing internally with GE’s other business lines.
Medical imaging has high barriers to entry and long-term secular growth drivers, including aging populations, greater demand for screening and surveillance, and increasing utilization of minimally invasive or noninvasive procedures.
Unlike its peers, GEHC is a major player in the pharmaceutical diagnostics market, which has high barriers to entry, attractive returns, and potential upside with respect to the theranostics market.
Bear case
GEHC does not have a long record of operating as a stand-alone company.
GEHC’s China business will likely see increasing competition from local competitors over time.
The recent launch of generic Omnipaque could start to affect the patient diagnostics segment in 2026.
By Jay Lee
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
GE HealthCare Technologies discussion 0 comments